In one paragraphArticle in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed, 4 citations in OpenAlex.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
13 authors at 3 institutions in 2 countries.
Mackenzie M LiebermanDepartment of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.ORCID 0000-0002-9480-3589 Jason H TongDepartment of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.ORCID 0000-0003-1795-9480 Nkechi U OdukweDepartment of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.
Colin A ChavelDepartment of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.
Terence J PurdonDepartment of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.ORCID 0009-0009-7824-7760 Rebecca BurchettDepartment of Pathology and Molecular Medicine, McMaster Immunology Research Centre, McMaster University, Hamilton, ON, Canada.ORCID 0000-0002-0328-2336 Bryan M GillardDepartment of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.ORCID 0000-0002-1403-6456 Craig M BrackettDepartment of Cell Stress Biology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.
A J Robert McGrayDepartment of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.ORCID 0000-0002-7145-8444 Jonathan L BramsonDepartment of Pathology and Molecular Medicine, McMaster Immunology Research Centre, McMaster University, Hamilton, ON, Canada.ORCID 0000-0003-2874-6886 Renier J BrentjensDepartment of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.
Kelvin P LeeIndiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN, 46202, USA.
Scott H OlejniczakDepartment of Immunology, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA.ORCID 0000-0001-6857-5554 Roswell Park Comprehensive Cancer Center · USMcMaster University Medical Centre · CAIndiana University Health · US
Funding
Two-Spirit Films in Indigenous Cancer HealthP30CA016056 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI MARK G FRATTINI · 1985 to 2026
$116.6MTumor Microenvironment and Metastasis ProgramP30CA082709 · NCI · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI Jun Wan · 1999 to 2026
$59.3MCD28-mediated Regulation of Multiple Myeloma Cell Proliferation and SurvivalR01CA121044 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI LEE, KELVIN P. · 2007 to 2023
$4.8MMULTIDISCIPLINARY APPROACHES TUMOR IMMUNOLOGYT32CA085183 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI Scott I. Abrams · 2001 to 2026
$3.1MUnderstanding mechanisms and consequences of T cell co-receptor regulated RNA maturationR01AI155499 · NIAID · ROSWELL PARK CANCER INSTITUTE CORP · PI OLEJNICZAK, SCOTT HENRY · 2021 to 2025
$2.6MIVIS Spectrum Imaging SystemS10OD016450 · OD · ROSWELL PARK CANCER INSTITUTE CORP · PI SPERNYAK, JOSEPH ANDREW · 2013 to 2013
$406kExamining the impact of endogenous CD28 signaling on CAR T cellsR03CA256122 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI OLEJNICZAK, SCOTT HENRY · 2021 to 2022
$168kNCI NIH HHS P30 CA016056NCI NIH HHS P30 CA082709NCI NIH HHS R01 CA121044NCI NIH HHS R03 CA256122NCI NIH HHS T32 CA085183NIAID NIH HHS R01 AI155499NIH HHS S10 OD016450
6 · The paper itselfAbstract
Recent FDA approvals of chimeric antigen receptor (CAR) T cell therapy for multiple myeloma (MM) have reshaped the therapeutic landscape for this incurable cancer. In pivotal clinical trials B cell maturation antigen (BCMA) targeted, 4-1BB co-stimulated (BBζ) CAR T cells dramatically outperformed standard-of-care chemotherapy, yet most patients experienced MM relapse within two years of therapy, underscoring the need to improve CAR T cell efficacy in MM. We set out to determine if inhibition of MM bone marrow microenvironment (BME) survival signaling could increase sensitivity to CAR T cells. In contrast to expectations, blocking the CD28 MM survival signal with abatacept (CTLA4-Ig) accelerated disease relapse following CAR T therapy in preclinical models, potentially due to blocking CD28 signaling in CAR T cells. Knockout studies confirmed that endogenous CD28 expressed on BBζ CAR T cells drove
Indexed as
CAR T cellsCD28co-stimulationmetabolismmultiple myelomatumor microenvironment
Identifiers
PMID38562904
PMCPMC10983979
OpenAlexW4393127926
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390